NEW YORK, October 7, 2016 /PRNewswire/ --
Stock-Callers.com reviews the most recent performances of the following Drug Manufacturing companies from the Healthcare sector: Amarin Corp. PLC (NASDAQ: AMRN), MEI Pharma Inc. (NASDAQ: MEIP), Biodel Inc. (NASDAQ: BIOD), and SciClone Pharmaceuticals Inc. (NASDAQ: SCLN). According to an article on the NASDAQ, Healthcare shares were flat in pre-market trade on Thursday, October 06, 2016. Learn more about these stocks by downloading their free report at:
On Thursday, shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 1.39 million shares. The stock ended the day at $3.16, which was 1.56% lower from the prior session. The Company's shares have gained 0.96% in the last one month, 44.29% over the previous three months, and 67.20% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.98% and 52.35%, respectively. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 54.75.
As per notes filed with the SEC, on September 22nd and 23rd, 2016, Amarin, through its subsidiary Amarin Pharmaceuticals Ireland Limited, received paragraph IV certifications from Roxane Laboratories, Inc. and Dr. Reddy's Laboratories, Inc., respectively, advising Amarin that such companies have filed abbreviated new drug applications with the U.S. Food and Drug Administration that seek regulatory approval for generic versions of Vascepa (icosapent ethyl) capsules.
On October 5th, 2016, research firm Cantor Fitzgerald initiated a 'Buy' rating on the Company's stock, issuing a target price of $6 per share. The free research report on AMRN is available at:
San Diego, California-based MEI Pharma Inc.'s stock finished yesterday's session 0.56% lower at $1.76 and with a total trading volume of 121,102 shares. The Company's shares have gained 24.38% over the previous three months and 10.00% on an YTD basis. The stock is trading above its 200-day moving average by 20.36%. Furthermore, shares of MEI Pharma, which focuses on the clinical development of drugs for the treatment of cancer, have an RSI of 46.89.
On September 6th, 2016, MEI Pharma reported that net cash used in operations was $17.9 million in FY16 compared to $28.1 million for FY15. Research and development expenses were $13.4 million for FY16 compared to $23.8 million for FY15. For FY16 net loss was $20.9 million, or $0.61 per share, compared to $32.7 million, or $1.16 per share, for the previous year. The complimentary report on MEIP can be downloaded at:
At the closing bell on Thursday, shares in Danbury, Connecticut headquartered Biodel Inc. saw a decline of 14.52%, ending the day at $0.50. The stock recorded a trading volume of 2.22 million shares, which was above its three months average volume of 574,520 shares. The Company's shares have advanced 19.05% in the last one month, 61.29% in the previous three months, and 47.06% on an YTD basis. The stock is trading 17.90% above its 50-day moving average and 41.25% above its 200-day moving average. Moreover, shares of Biodel, which focuses on the development and commercialization of treatments for diabetes in the US, have an RSI of 58.00.
As per notes filed with the SEC on October 3rd, 2016, Biodel has entered into an amended and restated share exchange agreement with Albireo Limited, a company registered in England and Wales, and the holders of Albireo's shares or notes convertible into Albireo shares, pursuant to which, Biodel will acquire the entire issued share capital of Albireo in exchange for newly issued shares of the company's common stock. Visit us today and download our complete research report on BIOD for free at:
Foster City, California headquartered SciClone Pharmaceuticals Inc.'s stock ended the day 1.81% lower at $10.29 and with a total trading volume of 186,855 shares. The Company's shares have gained 11.85% on an YTD basis. The stock is trading 1.02% below its 50-day moving average. Additionally, shares of SciClone Pharmaceuticals, which provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People's Republic of China, the US, and Hong Kong, have an RSI of 47.71.
On September 26th, 2016, SciClone Pharmaceuticals announced two important achievements in advancing the company's clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN® in sepsis, a life-threatening infectious disease in which the drug has previously demonstrated therapeutic benefit in a Phase 2 clinical trial. In addition, the first patient has been treated in the Phase 1 trial of PT-112, a multi-targeted platinum-pyrophosphate anticancer agent being developed for patients with advanced solid tumors. Get free access to your technical report on SCLN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA